Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott Taps Genentech Oncology Expertise For Two Phase I Compounds

This article was originally published in The Pink Sheet Daily

Executive Summary

Drug makers will collaborate on research and development of a Bcl-2 protein antagonist and VEGFR-based kinase inhibitor.

You may also be interested in...



Start-up BiPar Seeks Fast Track In PARP Inhibition

Firm’s lead DNA repair candidate wins spot in Windhover Information’s Top 10 unpartnered oncology projects.

Start-up BiPar Seeks Fast Track In PARP Inhibition

Firm’s lead DNA repair candidate wins spot in Windhover Information’s Top 10 unpartnered oncology projects.

Genta To File Complaint With FDA Over Statistical Analysis Of Genasense Data

Complaint relates to 2004 analysis of Genasense progression-free survival data in melanoma, presented to the Oncologic Drugs Advisory Committee.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel